OmniAb (NASDAQ:OABI) Receives “Buy” Rating from Benchmark

Benchmark reaffirmed their buy rating on shares of OmniAb (NASDAQ:OABI) in a research report sent to investors on Thursday morning,Benzinga reports. Benchmark currently has a $8.00 price objective on the stock.

Several other research analysts have also recently issued reports on OABI. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price target on shares of OmniAb in a research report on Friday, August 16th.

OmniAb Stock Down 4.7 %

Shares of OABI opened at $3.88 on Thursday. The company has a market capitalization of $458.46 million, a price-to-earnings ratio of -6.26 and a beta of -0.12. OmniAb has a 52-week low of $3.56 and a 52-week high of $6.72. The stock has a 50 day moving average price of $4.18 and a 200 day moving average price of $4.27.

Hedge Funds Weigh In On OmniAb

A number of hedge funds have recently modified their holdings of the business. Bleakley Financial Group LLC boosted its stake in OmniAb by 80.9% during the 1st quarter. Bleakley Financial Group LLC now owns 34,250 shares of the company’s stock worth $186,000 after purchasing an additional 15,321 shares during the period. Vanguard Group Inc. boosted its stake in shares of OmniAb by 1.1% during the first quarter. Vanguard Group Inc. now owns 5,713,539 shares of the company’s stock worth $30,967,000 after buying an additional 62,131 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of OmniAb by 13.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,843 shares of the company’s stock worth $146,000 after buying an additional 3,108 shares during the last quarter. Bellevue Group AG acquired a new position in OmniAb in the 1st quarter valued at about $62,000. Finally, Janus Henderson Group PLC raised its stake in OmniAb by 1.0% during the 1st quarter. Janus Henderson Group PLC now owns 7,859,438 shares of the company’s stock valued at $42,598,000 after acquiring an additional 81,541 shares during the last quarter. 72.08% of the stock is currently owned by hedge funds and other institutional investors.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.